About two-thirds of it, within a year. That's what the STEP 1 trial extension found when participants stopped semaglutide 2.4 mg after 68 weeks of treatment — they regained roughly 11.6 of the 17.3 percentage points of body weight they had lost, leaving a net retention of just 5.6% [1]. A 2026 BMJ meta-analysis of 37 studies confirmed this trajectory: weight regain after stopping semaglutide and tirzepatide averages 0.8 kg per month, projecting full return to baseline within about 18 months [2]. But those figures reflect abrupt cessation with no clinical support — the worst-case scenario. Planned discontinuation produces meaningfully better outcomes.

The Trial Data: What Actually Happened

The STEP 1 trial extension remains the most detailed look at post-semaglutide weight trajectories [1]. After 68 weeks on semaglutide 2.4 mg, participants averaged 17.3% weight loss from baseline. Then the drug stopped — cold, with no dose tapering and no transition protocol. Over the following year:

• Average regain: 11.6 percentage points of body weight
• Net weight loss retained: 5.6%
• Participants maintaining ≥5% loss at week 120: 48.2%
• Participants maintaining ≥10% loss at week 120: significantly fewer

For a 240-pound person who lost 41 pounds during treatment, that means regaining about 28 pounds — keeping roughly 13 pounds off a year later.

The SURMOUNT-4 trial told a similar story for tirzepatide: 82.5% of participants who switched to placebo after 36 weeks of treatment regained at least 25% of their initial weight loss within one year [3]. The regain pattern is consistent across the GLP-1 class.

How Fast Does It Come Back?

The BMJ meta-analysis gives the clearest answer [2]. Across 9,341 participants in 37 studies:

• All weight-loss medications: 0.4 kg per month average regain
• Semaglutide and tirzepatide specifically: 0.8 kg per month (double the overall average)
• Projected time to full regain: approximately 18 months for GLP-1 medications
• Comparison: regain after medication was four times faster than after behavioral programs alone

A separate 2025 meta-analysis in eClinicalMedicine analyzed 18 randomized trials with 3,771 participants and found average regain of 5.63 kg in obesity populations after GLP-1 discontinuation [4].

The convergence across independent analyses is notable. This isn't one outlier study — it's a consistent biological pattern.

The Metabolic Markers Don't Hold Either

Weight is one thing. What happens to the health improvements that came with the weight loss may matter more.

The STEP 1 extension tracked cardiometabolic markers through the discontinuation period [1]:

Blood sugar: HbA1c dropped 0.5 percentage points during treatment. After stopping, it climbed back 0.4 points — nearly erasing the benefit. Among those who had reversed prediabetes, normoglycemia rates fell from 93.6% at week 68 to 43.3% one year later.

Blood pressure: The BMJ review quantified the drift: systolic blood pressure rose 0.5 mmHg per month after stopping, diastolic 0.2 mmHg per month [2]. That's a clinically significant increase over 12-18 months.

Lipids — the partial exception: Reductions in C-reactive protein, improvements in HDL cholesterol, and lower triglycerides showed more persistence than weight or glycemic changes [1]. The mechanism isn't fully understood, but some lipid benefits appear to outlast the medication.

The overall BMJ projection: cardiometabolic markers return to pre-treatment levels within approximately 1.4 years — slightly faster than the weight [2].

Why Regain Is Biological, Not Behavioral

Semaglutide works by mimicking GLP-1, suppressing appetite, slowing gastric emptying, and quieting the reward-driven food preoccupation that many patients describe as "food noise." When the drug clears your system, those signals revert. Appetite returns to pre-treatment intensity. The mental ease around food disappears.

But there's a compounding problem: muscle loss during treatment. The SURMOUNT-1 DXA substudy found that roughly 25% of weight lost on tirzepatide was lean mass [5]. Other estimates range higher. Muscle is the primary driver of resting metabolic rate, so losing it during treatment means your body burns fewer calories at rest when you stop — while your appetite has returned to its original level. The resulting caloric imbalance makes regain almost mathematically inevitable unless you've actively protected muscle mass during treatment through resistance training and high protein intake.

This is why the conversation about semaglutide outcomes can't be reduced to "the drug works" or "the drug doesn't work." The drug works while you take it. The question is what metabolic position you're in when you stop.

What Continuing Treatment Looks Like

For comparison: the STEP 5 trial followed participants on semaglutide 2.4 mg for two full years [6]. They maintained 15.2% weight loss at 104 weeks, with weight stabilizing around week 60. No rebound. No gradual drift. The weight stayed off for as long as the medication continued.

That 15.2% sustained loss with continued treatment versus 5.6% net loss one year after stopping frames the central tension: semaglutide is effective therapy, but it may be effective chronic therapy for many patients — more analogous to blood pressure medication than an antibiotic course.

Most People Don't Stop by Choice

The clinical trial narrative assumes a deliberate decision to discontinue. Reality is different. A 2024 JAMA Network Open analysis found real-world GLP-1 discontinuation rates of 53.6% at one year and 72.2% at two years [7] — driven primarily by cost, insurance denials, and side effects rather than clinical decisions.

Patients who stop early — before reaching target weight, before stabilization, before any transition planning — face the worst outcomes. They've altered their biology temporarily without building the metabolic or behavioral foundation to sustain results. This is the population most at risk for full regain, and they represent the majority of people who stop the medication.

Tapering Changes the Equation

Every study showing dramatic regain — STEP 1, SURMOUNT-4 — used abrupt cessation. That's experimentally clean but does not reflect how discontinuation should be managed in clinical practice.

The American Pharmacists Association highlighted research showing that a structured 9-week dose reduction combined with behavioral coaching kept weight stable during the taper, with participants losing an additional 1.5% of body weight even after complete withdrawal — across 85 patients with 26 weeks of follow-up [8]. No FDA-standardized tapering protocol exists for semaglutide, but the clinical logic is straightforward: reduce gradually, monitor body composition and weight at each step, and adjust based on response.

How JumpstartMD Approaches Discontinuation

JumpstartMD builds the exit strategy into the program from day one — not as an afterthought when the prescription runs out. Their four-phase protocol:

Stabilization (3-6 months). After reaching target weight, patients remain on medication while metabolic signaling adapts to the new weight. This stabilization period — allowing what's sometimes called the metabolic "set point" to reset, though the concept is debated in obesity science — reduces the biological drive to regain.

Metabolic hardening. Before any dose reduction, the focus shifts to body composition. InBody scans track lean mass, and the clinical team ensures resistance training and protein targets are fully optimized. The goal: raise resting metabolic rate as high as possible before the medication decreases.

Gradual taper. Dose reductions happen over months, guided by body composition data and clinical response — not a calendar. If weight trends upward at a given dose step, the taper pauses or reverses.

Bridge therapy. When appropriate, patients transition to lower-intensity supports like metformin to manage residual insulin resistance without the full GLP-1 effect. Not everyone needs this, but having the option prevents the binary of full dose or nothing.

JumpstartMD's maintenance program data: 95% of patients sustain greater than 5% total body weight loss, and 87% sustain greater than 10% — substantially exceeding the 48.2% maintaining ≥5% in STEP 1's unsupported discontinuation [1].

Frequently Asked Questions

Q: How much of my weight loss will I keep after stopping semaglutide? A: Without structured support, roughly one-third — the STEP 1 extension showed participants retained 5.6% net body weight loss from a peak of 17.3% [1]. With a structured taper and clinical monitoring, the numbers are much better. JumpstartMD reports 87% of maintenance patients sustain greater than 10% total body weight loss.

Q: How quickly does the weight come back? A: About 0.8 kg (1.75 pounds) per month on average after stopping semaglutide, according to a 2026 BMJ meta-analysis [2]. At that rate, 30 pounds of weight loss would be fully regained in about 17 months. The regain is four times faster than after behavioral programs alone.

Q: Do the blood sugar and blood pressure improvements last? A: Mostly not. Blood sugar control (HbA1c) nearly returned to pre-treatment levels within one year of stopping. Prediabetes reversal rates dropped from 93.6% to 43.3%. Blood pressure rose about 0.5 mmHg systolic per month [1][2]. Some lipid improvements — HDL, triglycerides, CRP — showed more persistence.

Q: Is tapering better than stopping abruptly? A: Yes. Research shows that a 9-week structured taper with coaching kept weight stable during reduction [8], compared to the rapid regain seen with abrupt cessation in STEP 1 and SURMOUNT-4. There's no official protocol, which is why having a provider with a discontinuation framework matters. Call JumpstartMD at 408.478.3496 to discuss your situation.

Q: Should some people just stay on semaglutide? A: For some patients, long-term low-dose maintenance is the most evidence-based approach — particularly those with severe metabolic disease or strong genetic predisposition to regain. STEP 5 showed 15.2% sustained weight loss at two years with continued treatment [6]. The clinical question is finding the lowest effective dose, not choosing between full treatment and nothing.

Q: Why do most people stop taking semaglutide? A: Cost and insurance. Real-world discontinuation hits 53.6% at one year and 72.2% at two years [7]. Most people stop involuntarily — before reaching their goal weight and without any transition plan — which produces the worst outcomes.

Conclusion

Weight regain after stopping semaglutide is substantial and well-documented: two-thirds of lost weight within a year of abrupt cessation, with cardiometabolic improvements reverting on a similar timeline [1][2]. The biology is clear — withdraw the drug, and the appetite suppression, metabolic modulation, and food noise reduction disappear with it. But the degree of regain is not fixed. Muscle preservation during treatment, gradual tapering rather than abrupt cessation, behavioral habit formation while appetite is suppressed, and ongoing clinical monitoring during the transition all significantly improve retention. The medication works. The question is whether what surrounds it is designed for the moment the medication stops.

References

[1] J. P. H. Wilding et al., "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension," Diabetes, Obesity and Metabolism, vol. 24, no. 8, pp. 1553-1564, 2022. [Accessed: Feb. 11, 2026].

[2] S. West et al., "Weight regain after cessation of medication for weight management: systematic review and meta-analysis," BMJ, 2026. [Accessed: Feb. 11, 2026].

[3] L. J. Aronne et al., "Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial," JAMA, vol. 331, no. 1, pp. 38-48, 2024. [Accessed: Feb. 11, 2026].

[4] J. He et al., "Weight regain after discontinuation of GLP-1 receptor agonists: a systematic review and meta-analysis," eClinicalMedicine, vol. 79, 2025. [Accessed: Feb. 11, 2026].

[5] A. M. Jastreboff et al., "Body composition changes with tirzepatide: SURMOUNT-1 DXA substudy," Diabetes, Obesity and Metabolism, 2025. [Accessed: Feb. 11, 2026].

[6] D. Garvey et al., "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial," Nature Medicine, vol. 28, pp. 2083-2091, 2022. [Accessed: Feb. 11, 2026].

[7] S. S. Khan et al., "Real-world GLP-1 receptor agonist discontinuation rates," JAMA Network Open, 2024. [Accessed: Feb. 11, 2026].

[8] American Pharmacists Association, "Coming off GLP-1s slowly could be key to preventing weight regain," 2025. [Accessed: Feb. 11, 2026].